Trial of Unani medicine in the patients of Fungal infection of skin

A prospective Randomized standard control clinical trial of Unani formulation in the management of Dermatomycoses

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024609

Enrollment

104

Registered

2020-04-14

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Unani pharmacopeal formulation: as local application daily twice a day for 06 weeks Control Intervention1: Terbinafine cream: for local application daily twice a day for 6 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Patients with sign and symptoms of Dermatomycoses

Exclusion criteria

Exclusion criteria: Patient of Tinea capitis, Tinea ungium,impaired liver function, impaired renal function,Hypersensitivity of drugs, Malignancy, Epilepsy. Patients on prolong medication for any systemic disorder,on systemic corticoseteroid, disease modyfiny agents. Patients with secondary infection or any other infective disorder requiring long term treatment.Alcohalics, Drug Addicts,Pregnant or Lactating mother.

Design outcomes

Primary

Measure	Time frame
Unani formulation will be effective in treating DermatomycosesTimepoint: 08 weeks	—

Secondary

Measure	Time frame
Unani formulation will relieve of the symptomps of DermacomycosesTimepoint: 08 weeks	—

Countries

India

Contacts

Public ContactZamir Ahmad

Aligarh Muslim University

drzamiramrohi@gmail.com8475007594

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026